Last update 16 May 2024

Mazdutide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
+ [3]
Mechanism
GCGR agonists(Glucagon receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
Regulation-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ObesityNDA/BLA
CN
07 Feb 2024
Early-onset type II diabetesPhase 3
CN
29 Feb 2024
Diabetes Mellitus, Type 2Phase 3
CN
20 Nov 2022
Renal InsufficiencyPhase 1
CN
05 May 2023
Nonalcoholic SteatohepatitisIND Approval
CN
22 Mar 2023
HyperuricemiaPreclinical
CN
12 Jul 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
610
(iqjwpajqfr) = 主要研究终点顺利达成:玛仕度肽 4 mg和6 mg组受试者治疗32周后体重相对基线的百分比变化显著优于安慰剂组 fgkdoexsyx (kxsmiwnobe )
Met
Positive
09 Jan 2024
Phase 2
80
(iqmzpgrksi): difference = -15.4% (95% CI, -18.8 to -11.9)
Met
Positive
11 May 2023
placebo
Phase 2
248
mazdutide 3 mg
(cydzmhsdvc) = ebxkxdvdie zvoisijhyu (xegcbxbcej, 0.7)
Positive
14 Dec 2023
mazdutide 4.5 mg
(cydzmhsdvc) = ppnoqrewnh zvoisijhyu (xegcbxbcej, 0.7)
Phase 2
80
(mozvjtxdtr): Difference(%) = -15.4
Met
Positive
30 Oct 2023
placebo
Phase 1
36
(cfxvpymfqm) = Gastrointestinal adverse events and decreased appetite were the most common adverse events and mostly mild in severity wtyfpwpjio (xwcdwvhqie )
Positive
01 Sep 2021
Placebo
Not Applicable
-
48
vpfcpnrvgj(qmirpispmk) = agwpcpyqpk bbufllpjnk (ndkokzpidq )
-
01 Jun 2021
Not Applicable
-
(vdwbxrntta) = The most common treatment-emergent adverse events in both studies (decreased appetite, nausea, and diarrhea) were mostly mild in severity yyejegghhz (ozsdsftewb )
-
01 Jun 2022
Phase 2
250
(lposriyxgl) = bquhdtwzex smlcramxez (qfyynqhysc )
Positive
09 Nov 2023
Mazdutide 4.5 mg
(lposriyxgl) = jpqphceeir smlcramxez (qfyynqhysc )
Phase 3
731
mazdutide 4.0 mg
(wtqgzjnvkh) = the superiority test was further performed, and both mazdutide 4.0 mg and 6.0 mg achieved superiority to dulaglutide 1.5 mg. hqgdbsgsik (iroqeqebea )
Met
Superior
09 May 2024
mazdutide 6.0 mg
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free